A combination of pembrolizumab and the selective IDO inhibitor Epacadostat initially showed promising results increasing the anti-tumor activity in patients with advanced solid tumors in a phase I/II study (NCT02178722) (161). The gene discussed is IDO1; the disease is neoplasm.